Literature DB >> 30015149

Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis.

Yilun Deng1, Shaoping Li1, Lin Zhang1, Hou Jin1, Xiaoyi Zou2.   

Abstract

PURPOSE: The aim of this study was to assess the association between human leukocyte antigen (HLA) variants and lamotrigine (LTG)-induced cutaneous adverse drug reactions (cARDs).
METHODS: A comprehensive literature search was conducted on the relationship of HLA alleles with LTG-induced cADRs in Asian populations, through PubMed, Embase, and Cochrane Library. The last search was in February 2018. The pooled odds ratio (OR) with 95% confidence interval (95% CI) was used to access the strength of the association between an HLA allele and LTG-induced cADRs.
RESULTS: A total of 11 studies met the inclusion criteria and were enrolled in our meta- analysis, which were based on Chinese, Korean, and Thai populations. Among these populations, we observed that HLA-B*1502 is a risk allele for LTG-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Chinese populations (pooled OR 2.4, 95% CI: 1.20-4.78, P = 0.01), HLA-A*2402 was found to be a significant risk allele for both SJS/TEN (pooled OR 3.50, 95% CI: 1.61-7.59, P = 0.002) and maculopapular eruption (MPE) (pooled OR 2.14, 95% CI: 1.10-4.16, P = 0.03), and HLA-B*3303 was considered to be a protective marker for MPE in Chinese and Korean populations (pooled OR 0.2, 95% CI 0.06-0.64, P = 0.007).
CONCLUSIONS: In Asian populations, HLA-B*1502 is a risk factor for LTG-induced bullous lesions such as SJS/TEN in Chinese populations, and HLA-A*2402 is associated with the susceptibility to either SJS/TEN or MPE. HLA-A*3303 is a protective allele against LTG-induced MPE in Chinese and Korean populations.
Copyright © 2018 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HLA; Lamotrigine; Maculopapular eruption; Stevens-Johnson syndrome; Toxic epidermal necrolysis

Mesh:

Substances:

Year:  2018        PMID: 30015149     DOI: 10.1016/j.seizure.2018.06.024

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  6 in total

1.  Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors:  Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

2.  Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand.

Authors:  Napatrupron Koomdee; Chiraphat Kloypan; Pimonpan Jinda; Jiratha Rachanakul; Thawinee Jantararoungtong; Rattanaporn Sukprasong; Santirhat Prommas; Nutthan Nuntharadthanaphong; Apichaya Puangpetch; Maliheh Ershadian; Shobana John; Mohitosh Biswas; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

3.  Impact of Selected Initial Titration Schedules on Safety and Long-Term Effectiveness of Lamotrigine for the Treatment of Mood Disorders.

Authors:  Tomoyuki Nakamura; Masaru Tomita; Susumu Hirota; Takamasa Matsunaga; Naohisa Uchimura
Journal:  J Clin Psychopharmacol       Date:  2022-05-04       Impact factor: 3.118

Review 4.  Lamotrigine and Stevens-Johnson Syndrome Prevention.

Authors:  Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16

5.  HLA-A∗24:02 associated with lamotrigine-induced cutaneous adverse drug reactions: A systematic review and meta-analysis.

Authors:  Wanshu Li; Jie Wang; Hangjuan Lin; Gang Shen
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.817

Review 6.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.